Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Rapport Therapeutics Inc.
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07563881CT.gov Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 | — | Recruiting | — | — | — |
NCT07594119CT.gov Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures | — | Recruiting | — | — | — |
NCT07219407CT.gov A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures | — | Recruiting | — | — | — |
NCT06377930CT.gov Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Focal Epilepsy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rap-219 (this asset) | Rapport Therapeutics Inc. | P3 | BB · 66 |
| Eslicarbazepine Acetate | Sumitomo Pharma America, Inc. | P4 | A |
| Pregabalin | Yung Shin Pharm. Ind. Co., Ltd. | P4 | A |
| Topiramate | Mario Negri Institute for Pharmacological Research | P4 | A |
| Lacosamide | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | P4 | A |
| Lamotrigine | Dhaka Medical College | P4 | BBB |
| Cenobamate | Ono Pharmaceutical Co., Ltd. | P4 | BBB |
| Gabapentin | Mario Negri Institute for Pharmacological Research | P4 | BBB |
| Oxcarbazepine | Mario Negri Institute for Pharmacological Research | P4 | BBB |
+42 more in the Focal Epilepsy cohort
Other indications for Rap-219
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Epilepsy | — | P3 | B · 59 |
| Bipolar I Disorder | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rap-219 in Focal Epilepsy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rap-219-focal-epilepsy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →